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The human genome contains ∼30,000 CpG islands (CGIs). While CGIs
associated with promoters nearly always remain unmethylated, many
of the∼9,000 CGIs lyingwithin gene bodies becomemethylated during
development and differentiation. Both promoter and intragenic CGIs
may also become abnormally methylated as a result of genome rear-
rangements and in malignancy. The epigenetic mechanisms by which
some CGIs become methylated but others, in the same cell, remain
unmethylated in these situations are poorly understood. Analyzing
specific loci and using a genome-wide analysis, we show that transcrip-
tion running across CGIs, associated with specific chromatin modifica-
tions, is required for DNA methyltransferase 3B (DNMT3B)-mediated
DNA methylation of many naturally occurring intragenic CGIs. Impor-
tantly, we also show that a subgroup of intragenic CGIs is not sensitive
to this process of transcription-mediated methylation and that this
correlates with their individual intrinsic capacity to initiate transcription
in vivo.We propose a general model of how transcription could act as a
primary determinant of the patterns of CGI methylation in normal de-
velopment and differentiation, and in human disease.
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CGI methylation
Methylation of CpG dinucleotides plays a pivotal role inmammalian development and differentiation (1). Most CpG
dinucleotides are methylated, with the exception of those within
CpG islands (CGIs), which are usually unmethylated (2, 3). Al-
though several mechanisms have been proposed to explain how
CGIs normally escape methylation (reviewed in ref. 1), they do not
always remain unmethylated. In particular, while most promoter
CGIs remain unmethylated, ∼9,000 CGIs within gene bodies (in-
tragenic) are more likely to become methylated (4, 5).
Many intragenic CGIs become methylated during development,
and this often coincides with transcription of the gene within which
they lie; typical examples are CGIs in imprinted genes and at the X
inactivation center (6, 7). In addition, aberrant methylation of CGIs
has been reported in inherited and acquired genomic rearrange-
ments when CGIs become abnormally located within the body of
another, transcriptionally active gene (8–10). Such examples strongly
suggest that aberrant or naturally occurring transcription passing
through CGIs is, in some way, linked to their DNA methylation.
To address how transcription running across a CGI may deter-
mine whether or not it becomes methylated, we took an experi-
mental approach to study in detail the mechanism by which a CGI
located at the α-globin locus becomes methylated when incorpo-
rated into a newly formed transcriptional unit causing a human disease
[α-thalassemia (10)] (Fig. 1). To relate these findings to endogenous
intragenic CGIs, we also analyzed a previously described, naturally
occurring CGI associated with the rhomboid 5 homolog 1
(RHBDF1), which becomes methylated during normal devel-
opment in vivo (11) (Fig. 1).
In both cases, we show that methylation of these specific CGIs
is associated with transcription traversing the CGI, a reduction of
H3K4me3, a gain of H3K36me3, and DNA methyltransferase 3B
(DNMT3B)-mediated DNA methylation. At these specific loci,
we experimentally determined the order in which these events
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lead to establishment of methylation and silencing of the tran-
scribed CGIs. Importantly, we finally show that transcription-
mediated DNA methylation is a general mechanism responsible
for silencing naturally occurring intragenic CGIs throughout the
genome. Interestingly, however, we find that not all CGIs be-
come methylated and silenced when transcribed: CGIs that act
as highly active initiators of transcription remain unmethylated.
These findings indicate that, in contrast to what is seen at gene
body regions, transcription traversing a CGI is not always suffi-
cient to drive its methylation and silencing but also depends on
the degree to which such a CGI initiates transcription itself.
Results
Silencing of a CGI Located Within a Newly Formed Transcriptional Unit
Is Associated with Enrichment in H3K36me3 and H3K9me3. We have
previously shown that silencing of HBA2 expression on the
rearranged allele of an individual (ZF) with α-thalassemia is
caused by de novo DNA methylation of the HBA promoter CGI
in the presence of antisense transcription from the truncated
LUC7L gene (10) (Fig. 1). Here, we further characterized the
associated epigenetic profile of the rearranged ZF allele. Ana-
lyzing EBV-transformed lymphocytes from ZF (EBV-ZF) and a
normal individual (EBV-RN), we found no differences in the
levels of H3K4me3 (Fig. 2A, Left). The enrichment for this mark
was low at HBA2, consistent with the fact that this gene is not
expressed in lymphocytes. By contrast, we found an increase in
H3K9me3 in EBV-ZF compared with EBV-RN (Fig. 2A, Center).
Given that the HBA genes in nonexpressing cells are normally
silenced by the polycomb system (H3K27me3) and not by K9
methyltransferases (H3K9me3) (12), it seemed most likely that
the enrichment of H3K9me3 only in EBV-ZF originates from
the abnormal ZF chromosome. Most notably, we also found
enrichment of H3K36me3 at the HBA-CGI and HBA-ex3 regions
only in EBV-ZF cells (Fig. 2A, Right). These observations are con-
sistent with previous data showing antisense transcription occurs
across HBA2 on the ZF chromosome but not on the normal copy of
chromosome 16 (10).
To determine whether the enrichment of H3K9me3 and H3K36me3
was similarly restricted to the rearranged ZF allele, we analyzed
two independently isolated mouse erythroleukemia (MEL) in-
terspecific hybrid cell lines carrying either the normal (MELx16)
or rearranged (MELxZF) copy of human chromosome 16 (13).
In the erythroid-poised environment of MEL cells, in contrast to
the normal hybrids (MELx16), we detected no enrichment of
H3K4me3 in MELxZF hybrids (Fig. 2B, Left), consistent with
the ZF chromosome carrying a silenced and DNA-methylated
HBA2 gene (13). However, in MELxZF hybrids (but not MELx16
hybrids), we found enrichment of H3K9me3 (Fig. 2B, Center) and
H3K36me3 (Fig. 2B, Right) at the HBA-CGI and HBA-ex3, sup-
porting the hypothesis that transcription through the CGI is as-
sociated with these chromatin modifications and silencing of the
HBA2 gene on the ZF chromosome.
Transcription Is Required to Establish Epigenetic Silencing of the
HBA2 CGI. Epigenetic silencing of the HBA2 CGI observed in
ZF is faithfully recapitulated in mouse models using a construct
[ZFα-antisense (ZFαAS); Fig. 1] in which an α-globin enhancer/
HBA2 cassette is linked to a fragment spanning the LUC7L CGI,
which, in turn, produces an RNA transcript that runs across the
α-globin CGI. In this model, silencing of the α-globin CGI is
established before the specification of the three germ layers both
in vivo and during in vitro differentiation of mouse embryonic
stem (mES) cells (10). Therefore, we used this experimental
model to investigate the role of transcription in de novo DNA
methylation of the CGI. As a control, we used mES clones
harboring the ZFαS construct in which the LUC7L transcription
is driven away from HBA2 CGI rather than running across the
CGI (10).
To determine if this system established chromatin signatures
similar to those observed in the EBV-ZF and MELxZF cell lines,
we established chromatin profiles in ZFαAS and ZFαS mES cells
and in in vitro-differentiated embryoid bodies (EBs) at day 7.
Despite transcription through the HBA2 CGI in ZFαAS cells, we
found no significant differences in the levels of H3K4me3 at the
HBA2 gene in undifferentiated mES cells; however, at day 7,
H3K4me3 is enriched at the HBA-CGI and HBA-ex3 in ZFαS
Fig. 1. Short arm of chromosome 16 (chr16) harbors exemplar loci to in-
vestigate the mechanism of DNA methylation within transcribed CGIs.
Schematic representation of the human chr16 encompassing the HBA locus
in a normal allele (α16p) and in the ZF-deleted allele (α−ZF). The hypo- and
hypermethylated status of CGIs investigated in this study is marked by empty
and filled lollipops, respectively. The positions of qPCR assays used for ChIP
are shown as numbered black bars (1 = RHBDF1 intron 17, 2 = RHBDF1 in-
tragenic CGI, 3 = RHBDF1 intron 3, 4 = RHBDF1 promoter CGI, 5 = 5′ HBA, 6 =
HBA CGI, 7 = HBA exon 3, 8 = LUC7L gene body, 9 = LUC7L promoter). Gray
rectangles indicate the fragments present in the ZFαAS construct.
Fig. 2. HBA2 promoter CGI on the ZF allele is associated with loss of
H3K4me3 and enrichment in H3K9me3 and H3K36me3. ChIP was performed
with antibodies to H3K4me3, H3K9me3, and H3K36me3 in EBV-transformed
lymphocytes from an individual carrying two normal copies of chromosome
16 (EBV-RN) or ZF (EBV-ZF) (A), and in MEL hybrids carrying a normal copy
(MELx16) or the ZF copy (MELxZF) of human chromosome 16 (B). Precipitated
DNA fragments were used to amplify regions labeled 6, 7, and 8 in Fig. 1. P,
positive control for EBV lymphocytes (A; human ACTB promoter for
H3K4me3, human 18S for H3K9me3, human ACTB gene body for
H3K36me3) and for MEL hybrids (B; mouse Actb promoter for H3K4me3,
mouse 18S for H3K9me3, mouse Ccna2 gene body sequence for H3K36me3);
N, negative control for EBV lymphocytes (A, human RHBDF1 promoter for all
modifications) and for MEL hybrids (B, mouse intergenic region for
H3K4me3 and H3K36me3; human RHBDF1 promoter for H3K9me3). P values
were calculated by t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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but not ZFαAS EBs (Fig. 3A). Consistent with the HBA2 CGI
having a bivalent chromatin signature in mES cells (14–16),
we found that ZFαS clones maintained the H3K4me3 and
H3K27me3 histone modifications at the HBA2 CGI in mES cells
(Fig. 3A, Left and SI Appendix, Fig. S1A, Left). By contrast,
H3K27me3 was depleted at the HBA2 CGI in ZFαΑS clones,
which showed significant enrichment for H3K9me3 upon dif-
ferentiation (SI Appendix, Fig. S1 A and B). These data show that
the loss of H3K4me3 in ZFαΑS clones is not dependent on the
polycomb (H3K27me3) pathway.
These contrasting profiles in ZFαΑS and ZFαS strongly suggest
that transcription traversing the α-globin CGI is the key event
leading to DNA methylation and silencing. We therefore used a
different approach to further test this hypothesis. We made mES
cell clones carrying a construct in which the β-globin transcription
terminator (17) prevents transcription from the LUC7L promoter
running through the HBA2 CGI (ZFαAS-STOP; SI Appendix, Fig.
S2 A and B). In ZFαAS-STOP clones, with very low/undetectable
transcription through the HBA2 CGI, this CGI remained unme-
thylated and the HBA2 gene was not silenced upon differentiation
(SI Appendix, Fig. S2 C and D). Consistent with this, the HBA2
CGI also remained modified by H3K4me3 rather than acquiring
H3K9me3 (SI Appendix, Fig. S2E). These experiments thus pro-
vide complementary evidence supporting the role of transcription
in this methylation-mediated silencing.
To prove that transcription running through the HBA2 CGI,
rather than the resulting RNA and its intermediates, is responsible
for DNA methylation of the CGI, we performed Northern blots and
small RNA-sequencing (RNA-Seq) in our system. We did not detect
any HBA2-specific small RNAs in undifferentiated or differentiating
ZFαAS cells (SI Appendix, Fig. S2 F and G). These observations,
together with previous data (10), show that the epigenetic changes
that lead to HBA2 silencing in the ZF context rely on a mechanism
that is primarily dependent on transcription in cis rather than the
RNA transcript, per se, as seen in other systems (18).
Epigenetic Silencing of the HBA2 CGI Occurs During Differentiation.A
recent report showed that transcription-mediated deposition of
H3K36me3 within gene bodies can form a docking site for the de
novo DNMT3B, thus targeting DNA methylation to transcribed
regions (19). This may also explain how transcription, per se,
may be responsible for silencing of the HBA2 CGI in ZF via
DNA methylation. Consistent with this, we found significant
enrichment of H3K36me3 at HBA2, particularly when ZFαAS
clones were differentiated (Fig. 3B). However, in contrast to
what was previously seen at gene body regions (19), the presence
of H3K36me3 at the HBA2 CGI in undifferentiated ZFαAS mES
cells was not sufficient to mediate methylation of this CGI.
The inducible nature of the ZFαAS mES system enabled us to
dissect the timing and order of events leading to this type of
epigenetic silencing. We found that H3K4me3 decreases across
the HBA2 locus in ZFαAS between days 2 and 4, with the lowest
enrichment seen at day 6 (SI Appendix, Fig. S3A, Left). By con-
trast, an increase in H3K9me3 and H3K36me3 was observed at
all sites in ZFαAS between days 2 and 4 of differentiation (SI
Appendix, Fig. S3A, Center and Right). This correlates with the
acquisition of de novo DNA methylation at the HBA2 CGI that
also occurs between days 2 and 4 of differentiation (10) (SI
Appendix, Fig. S4). A plot of the values relative to day 0 of the
enrichment for the histone modifications as measured by ChIP
and of the percentage of (%) methylation at the Eag1 site as
measured by Southern blotting indicates that HBA2 silencing is
established between days 2 and 4 of ZFαAS differentiation and is
associated with a loss of H3K4me3 and a gain of H3K36me3,
H3K9me3, and DNA methylation at the abnormally transcribed
HBA2 CGI (Fig. 3C, Left). By contrast, no significant changes in
any chromatin modifications were seen at the LUC7L promoter
CGI (Fig. 3C, Right). It must be noted that we have combined in
the plots enrichment-based ChIP at and surrounding the 60-bp
HBA-CGI region amplified by PCR with the % DNA methyl-
ation at the 6-bp Eag1 recognition site, and this probably un-
derlies the apparent paradoxical retention of H3K4me3 at the
HBA2 CGI at day 4 when DNA methylation appears to be near
maximal (Fig. 3C, Left). The data from bisulfite sequencing
suggest that although the Eag1 site is >65% methylated, the
region that includes the HBA2 transcription start site has the
higher concentration of unmethylated or lowly methylated CpGs
at day 4, consistent with possible H3K4me3 retention at this time
point (SI Appendix, Fig. S4).
DNMT3B Is Required for Methylation of the HBA2 CGI. To determine
whether DNMT3B is the DNMT responsible for the deposition
of DNA methylation at the HBA2 CGI in ZF, we generated
Fig. 3. Transcription-mediated deposition of H3K36me3 precedes re-
cruitment of DNMT3B to HBA2 in ZF. H3K4me3 (A) and H3K36me3 (B) ChIP
performed in ES cells (Left) and EBs (Right) from ZFαS and ZFαAS cell lines is
shown. Precipitated DNA fragments were used to amplify regions labeled 5,
6, 7, and 9 in Fig. 1. P, positive control (mouse Ccna2 gene body); N, negative
control (mouse intergenic region). P values were calculated by t test: *P <
0.05, **P < 0.01, ***P < 0.001. Changes in DNA methylation, H3K4me3,
H3K36me3, and H3K9me3 during in vitro differentiation of ZFαAS (C) and
8bb3 (D) cells are shown. Percentages of DNA methylation at the Eag1 site
within the HBA2 and LUC7L promoter CGIs were calculated as the ratio of
methylated to total signal by Southern blotting (SI Appendix, Fig. S4), while
changes in relative enrichment of histone modifications at HBA-CGI and
LUC7L-prom were measured by ChIP. Data points displayed for each modi-
fication are the log2 of the ratios relative to their respective day 0 value.
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clones stably transfected with the ZFαAS construct in wild-type
(J1-1) and Dnmt3b−/− (8bb) mES cells (20). To compare the
epigenetic profiles in undifferentiated and differentiated mES
cells, we used the cardiomyocyte differentiation system because
mES cells lacking DNMTs are most easily differentiated to car-
diomyocytes (21) and the dynamics of HBA2 silencing in ZFαAS
cells are maintained under these conditions (SI Appendix, Fig. S1 C
and D). Consistent with the data from ZFαAS cells, the HBA2 CGI
became methylated upon differentiation of J1-1 cells (SI Appendix,
Fig. S3B). In contrast to this, we did not detect methylation at
HBA-CGI in Dnmt3b−/− cells carrying the ZFαAS construct
(8bb2 and 8bb3 in SI Appendix, Fig. S3B) even though they dif-
ferentiated normally (SI Appendix, Fig. S3C). This indicates that
DNMT3B is the main methyltransferase responsible for methyl-
ation of the HBA2 CGI in ZF, and is consistent with recently
published data showing that DNMT3B methylates actively tran-
scribed regions of the genome (19). We therefore further charac-
terized the epigenetic profiles in Dnmt3b−/− cells and found that
the HBA2 CGI in undifferentiated Dnmt3b−/− cells was enriched in
both H3K4me3 and H3K36me3. Upon EB differentiation, there
was a decrease in H3K4me3 accompanied by an increase in
H3K36me3; importantly, however, this occurred without estab-
lishment of DNAmethylation at the Eag1 site in theHBA2 CGI (SI
Appendix, Fig. S3B), H3K9me3 at HBA-CGI, or any of the other
HBA2 sites tested (SI Appendix, Fig. S3D). These observations at
the HBA2 CGI in Dnmt3b−/− cells are highlighted by plotting the
ES cell and EB values for enrichment in the different histone marks
and % DNA methylation at the Eag1 site relative to the ES cell
(Fig. 3D, Left). No significant changes in any chromatin modifica-
tions were seen at the LUC7L promoter CGI (Fig. 3D, Right).
These data support an order of events whereby transcription
through the H3K4me3-enriched HBA2 CGI is accompanied by
deposition of H3K36me3. Upon differentiation, a decrease in the
level of H3K4me3 and an increase in the level of H3K36me3 are
followed by DNA methylation and deposition of H3K9me3 at the
HBA2 CGI, which seems to occur at the same time and requires
DNMT3B, probably due to the two enzymatic activities being part
of the same multiprotein complex (22).
Transcriptional Elongation Through CGIs Has Different Effects on
Specific CGIs. To test whether transcription running through a
CGI is a general mechanism for differentiation-induced CGI
methylation and gene silencing, we analyzed three additional hu-
man genes associated with promoter CGIs: the muscle-specific
myogenic differentiation 1 (MYOD1) gene and the ubiquitously
expressed ubiquitin C (UBC) and actin B (ACTB) genes. As be-
fore, transcriptional elongation across each CGI was driven by the
LUC7L promoter (Fig. 4 A, C, and E). Transcription through each
of these genes’ CGIs was detected in both mES cells and day 8 EBs
(SI Appendix, Fig. S5A). Transcription traversing the CGIs asso-
ciated with MYOD1 and UBC was associated with loss of expres-
sion (SI Appendix, Fig. S5B), but, surprisingly, this was not the case
for ACTB (SI Appendix, Fig. S5B). Upon differentiation into EBs,
the MYOD1 (SI Appendix, Figs. S5C and S6) and UBC (SI Ap-
pendix, Figs. S5D and S7) CGIs become methylated, with associ-
ated loss of H3K4me3 and enrichment of H3K36me3 and
H3K9me3 (Fig. 4 B and D). By contrast, the ACTB CGI remained
free of methylation (SI Appendix, Figs. S5E and S8) and showed
increased levels of H3K4me3 and decreased levels of H3K36me3
(Fig. 4F). Therefore, we can conclude that transcription-mediated
silencing is observed at the promoter CGIs of both tissue-specific
(MYOD) and ubiquitously expressed (UBC) genes; however, not
all CGIs are susceptible to silencing mediated by transcriptional
elongation passing through these elements.
Epigenetic Silencing at a Naturally Occurring Intragenic CGI.We next
addressed whether these experimental observations illustrate a
general mechanism by which naturally occurring intragenic CGIs
become methylated during differentiation and development in vivo.
We initially studied the RHBDF1 gene, which is located at
16p13.3, ∼100 kb from theHBA gene cluster (Fig. 1) and encodes a
rhomboid protease-like protein (23, 24). RHBDF1 has a promoter
CGI that is unmethylated in all tissues and an intragenic CGI that
we previously noted is methylated in all somatic cells (11). Im-
portantly, this intragenic CGI is unmethylated in sperm, where
RHBDF1 is not transcribed, while it is methylated in human embry-
onic stem (hES) cells, where RHBDF1 is expressed. Subsequently, in
development, the intragenic CGI remains methylated in all somatic
cells regardless of the level of RHBDF1 RNA expression (Fig. 5A).
This shows that transcription may be required to establish but not
to maintain methylation of the RHBDF1 intragenic CGI during
development. This CGI therefore provides an experimental model
to analyze intragenic CGI methylation in vivo.
To determine if transcription is required to establish DNA methy-
lation at the RHBDF1 intragenic CGI, we used a recombination-
mediated cassette exchange (RMCE) system to target sequences
of interest, with high efficiency, into a single defined genomic
location within the mouse α-globin locus (25) (SI Appendix, Fig.
S9A). This well-characterized locus represents a neutral chromatin
environment in mES cells as it is transcriptionally silent and lacks
both active (H3K4me3) and repressive (H3K27me3) histone
marks (SI Appendix, Fig. S9B). This region also has no effect on the
methylation status of integrated DNA (SI Appendix, Fig. S10).
Therefore, this system allows us to investigate the contribution of
the inserted sequences to their methylation status within an ap-
parently “neutral” chromosomal environment.
Fig. 4. LUC7L-driven transcription can epigenetically silence promoter CGI
of the MYOD and UBC genes but not ACTB CGI. A schematic diagram of
MYOD1-AS (A), UBC-AS (B), and ACTB-AS (C) constructs is shown, with the
position of ChIP primers indicated. Changes in H3K4me3, H3K9me3, and
H3K36me3 at MYOD-CGI (D), UBC-CGI (E), and ACTB-CGI (F) in ES cells and
day 7 EBs are shown. Data displayed for each modification are the log2 of
the ratios relative to their respective ES cell value.
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Epigenetic Silencing of the RHBDF1 Intragenic CGI Depends on
Transcription from the Associated Promoter. To determine if the
DNA sequence of the RHBDF1 intragenic CGI alone is suffi-
cient to drive DNA methylation independent of transcription
and the normal chromosomal context of the gene, we first in-
tegrated a DNA fragment encompassing the RHBDF1 intragenic
CGI alone (Fig. 5) into the RMCE system (SI Appendix, Fig.
S9A). Analysis of targeted clones showed that the intragenic
CGI, on its own, remained unmethylated in the RMCE system
(intragenic CGI clones 1, 2, and 3 in Fig. 5B). Moreover, in two
of the three clones tested, this CGI became unmethylated even
when its DNA sequence was methylated in vitro before inte-
gration (in vitro-methylated intragenic CGI clones 1 and 2 in Fig.
5B), consistent with previous studies showing that a high CpG
density in mES cells, per se, can create stable nonmethylated
CGIs (26, 27). Therefore, the RHBDF1’s intragenic CGI sequence
alone is not sufficient to recapitulate its endogenous pattern of
methylation, supporting the hypothesis that the intragenic context
is critical to its methylation.
These findings suggested that transcription originating from
the promoter of the RHBDF1 gene may be required for DNA
methylation. We therefore integrated the RHBDF1 intragenic
CGI in the context of the RHBDF1 gene with (RHBDF1+P) or
without (RHBDF1−P) its promoter into the RMCE system (SI
Appendix, Fig. S11A). We confirmed that RHBDF1 is expressed
in RHBDF1+P but not in RHBDF1−P mES cells (SI Appendix,
Fig. S11B). In undifferentiated cells, we found that the intra-
genic CGI is less heavily methylated in both RHBDF1+P and
RHBDF1−P clones than at its normal endogenous locus in hES
cells (Fig. 6). This may be simply explained by suboptimal ex-
pression of RHBDF1 in this system. Nevertheless, we observed a
small but significant difference in DNA methylation at the 3′ end
of the CGI when comparing RHBDF1+P and RHBDF1−P clones
in these undifferentiated cells.
When RHBDF1+P and RHBDF1−P clones were differentiated
into day 7 EBs (Fig. 6), the intragenic RHBDF1+P CGI became
Fig. 5. RHBDF1’s intragenic CGI sequence is not sufficient to recapitulate its
endogenous methylation status in the RMCE system in mES cells. (A) DNA
methylation and expression of the human RHBDF1 gene and the context of the
intragenic CGI. The RHBDF1 gene, located on human chromosome 16, has two
CGIs: one at the promoter and one within the gene body. A snapshot of
RHBDF1 from the UCSC Genome Browser is shown, with plotted, publicly
available methylation profiles by Bio-CAP-Seq from testes and liver (peaks
represent unmethylated DNA), BS-Seq data from hES (peaks represent meth-
ylated DNA), and RNA-Seq data from hES and liver. (B) DNA methylation status
of the intragenic CGI of RHBDF1 was analyzed by sequencing of bisulfite-
converted DNA from hES cells (track in red), three RMCE-derived mES clones
with integrated unmethylated (tracks in purple) and in vitro-methylated (tracks
in dark blue) sequences of human RHBDF1 intragenic CGI, and methylated
control genomic DNA (track in black). Individual CpG coverage in bisulfite
analyses is indicated below each DNA methylation track.
Fig. 6. Upon differentiation, the intragenic CGI becomes hypermethylated in
the context of RHBDF1+P. The DNA methylation status of the intragenic and
promoter CGIs of RHBDF1 was analyzed by sequencing of bisulfite-converted
DNA from hES cells (track in red), three RMCE-derived mES cell/EB day 7 clones
with integrated RHBDF1+P (tracks in blue) and RHBDF1−P (tracks in green), and
methylated control genomic DNA (track in black). Individual CpG coverage in
bisulfite analyses is indicated below each DNA methylation track. The average
DNA methylation difference of individual CpGs within the intragenic CGI be-
tween +P and −P RMCE clones is displayed in purple.
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heavily methylated. By contrast, the RHBDF1 intragenic CGI re-
mained largely unmethylated in RHBDF1−P clones (Fig. 6). These
data show that the context of the CGI within the RHBDF1 gene
alone is not sufficient to drive its methylation; rather, it is tran-
scription from the RHBDF1 promoter that is critically required.
The increased CGI methylation in RHBDF1+P clones during in
vitro differentiation is associated with significant increases in the
level of RHPDF1+P nascent transcription (Fig. 7A), showing a
correlation between level of transcription and methylation of the
intragenic CGI.
Using ChIP in RHBDF1+P clones we found that the distri-
bution of H3K36me3 within RHBDF1 follows that typically ob-
served at expressed genes: no enrichment at the transcription
start site, with a gradual increase throughout the gene body and
maximum levels close to the transcription termination site
(Fig. 7B). Moreover, the level of H3K36me3 further increases
upon in vitro differentiation (Fig. 7B). Taken together, these
data are consistent with transcription through the intragenic CGI
increasing H3K36me3 and consequently recruiting DNMT3B,
which then promotes de novo DNA methylation.
The Intragenic CGI Acts as a Promoter in the Absence of a Transcriptionally
Active Promoter of RHBDF1. Since the RHBDF1 intragenic CGI is
predominantly unmethylated in RHBDF1−P EBs, we investigated
whether this is associated with changes in its epigenetic signature. We
showed that the low level of DNAmethylation in RHBDF1−P EBs is
associated with a gain in the H3K4me3 modification characteristic of
active promoters (SI Appendix, Fig. S12A). Of particular note, we
observed an atypical distribution of H3K36me3 throughout the
RHBDF1 gene in RHBDF1−P compared with RHBDF1+P clones.
Interestingly, in RHBDF1−P, there is now a small dip in enrichment
of H3K36me3 at the intragenic CGI in contrast to the surrounding
amplicons (SI Appendix, Fig. S12B). This is consistent with the pat-
tern normally seen at promoter CGIs (28). It therefore seemed
possible that, in the absence of the RHBDF1 promoter CGI, the
intragenic CGI in RHBDF1 now acts itself as a promoter since it is no
longer silenced by RNA transcripts running through this element.
To examine this, we generated a map of transcription initiation
sites in RHBDF1+P- and RHBDF1−P-derived EBs using a modified
version of the CapSeq method (29) and found that the CGI in
RHBDF1−P EBs gives rise to multiple transcription initiation sites
(SI Appendix, Fig. S12C). To investigate this further and obtain a
quantitative measurement of transcription initiation, we carried out a
strand-specific 5′ RACE assay. This confirmed that in EBs, the CGI
in RHBDF1−P clones produced twofold higher levels of nascent
sense transcripts than the CGI in RHBDF1+P clones (SI Appendix,
Fig. S12D). These data show that, in the absence of transcription
running through its sequence, the intragenic CGI of RHBDF1
acts as a typical promoter CGI.
Global Analysis of Intragenic CGIs. Having demonstrated experi-
mentally that transcription across a CGI and its modification by
H3K36me3 is correlated with DNA methylation at the two
specific intragenic CGIs described above, we asked whether this
is a general phenomenon leading to methylation of intragenic
CGIs throughout the genome. Based on UCSC Genome Browser
annotations, we first classified 27,718 human CGIs into 13,478
promoter, 8,795 intragenic, and 5,445 intergenic islands. The pro-
moter CGIs were further divided into 10,229 truly promoter and
2,836 alternative promoter CGIs. The latter act as a promoter CGI
for one isoform of a gene and as an intragenic CGI of another
isoform of the same gene (Fig. 8A).
The majority of promoter (∼95%) and alternative promoter CGIs
(∼85%) are unmethylated (≤45% methylation). Their hypomethy-
lated state is associated with H3K4me3 enrichment and lack of
H3K36me3 (SI Appendix, Fig. S13). In contrast, the majority (∼65%)
of intragenic CGIs are DNA-methylated (≥55% methylation). The
hypermethylated state of these CGIs is associated with traversing
transcription elongation, H3K36me3 enrichment, and lack of H3K4me3
and H3K27me3 (Fig. 8 B and C and examples in SI Appendix, Fig.
S14). The remaining intragenic CGIs are not methylated but ap-
pear to be silenced by a polycomb-mediated mechanism as they are
neither transcribed nor enriched in H3K36me3 but are marked by a
bivalent H3K4me3 and H3K27me3 chromatin signature (Fig. 8C).
We next analyzed alternative promoter CGIs and found
that ∼14% of these are DNA-methylated. Methylation of these
CGIs is associated with traversing transcription elongation and
H3K36me3 enrichment (SI Appendix, Fig. S13 B and D), suggesting
that they are also methylated in a transcription-dependent mech-
anism. Of interest, this is in contrast to methylated promoter CGIs
that are neither transcribed nor marked by H3K36me3, H3K4me3,
and H3K27me3 (SI Appendix, Fig. S13 A and C), suggesting an
alternative mechanism of methylation that is independent of
transcription.
The gene body CGIs are smaller, with an average size of 513 ±
494 bp compared with the promoter CGIs, with an average size
of 995 ± 725 bp. However, the % CpG and % GC within the
identified classes of CGIs are similar (the difference between
gene body CGIs and the other classes is less than 1.68% and less
than 0.65%, respectively) (SI Appendix, Fig. S15). We did not
detect any known motif enrichment within the gene body CGIs
compared with all CGIs or the promoter CGIs only.
Therefore, our data indicate that when CGIs form a part of a
transcriptional unit in early development, a large proportion of
such islands lose H3K4me3, are modified by H3K36me3, and
become DNA-methylated and silenced as development pro-
gresses. This applies to both transcribed alternative promoters
and intragenic CGIs.
The Methylation Status of Intragenic CGIs Traversed by Transcription
Elongation Depends on Their Intrinsic Activity as Promoters. Here,
we have shown that whether or not a specific alternative promoter
or intergenic CGI becomes methylated depends on its chromo-
somal context and, in particular, on whether or not transcription
passes through the CGI at some point. Although many CGIs be-
come methylated as transcription traverses them, this is not always
the case, as illustrated by the ubiquitously expressed ACTB CGI
Fig. 7. Increase in the RHBDF1+P intragenic CGI DNA methylation upon in
vitro differentiation is associated with higher gene expression and H3K36me3
enrichment. (A) RHBDF1+P nascent transcription level was measured by real-
time RT-PCR in mES cells on days 0 and 7 of in vitro differentiation. The data
were normalized to Rm18s and displayed as the average ± SD of three in-
dependent experiments. A paired t test was used to calculate statistical sig-
nificance: **P < 0.01. (B) ChIP was performed using antibodies to H3K36me3,
H3, or a control nonspecific IgG in RHBDF1+P mES cells and day 7 EBs. The
precipitated DNA fragments were used to amplify regions labeled 1, 2, 3, and
4 in Fig. 1. The data were normalized to INPUT and H3 level, and are displayed
as the average ± SD of three independent experiments relative to the highest
value. A paired t test was used to calculate statistical significance: * P < 0.05,
**P < 0.01. The gene body sequences of mouse Nprl3 and Ccna2 served as
positive controls, and two intergenic sites served as negative controls.
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that remains unmethylated when experimentally placed in the tran-
scription unit of the LUC7L gene. So, what determines which in-
tragenic CGIs become methylated and which remain unmethylated?
Taking ACTB as an example, it is more highly expressed in
ZFαAS cells than the HBA2, UBC, and MYOD genes (SI Ap-
pendix, Figs. S5 and S16): Could it be that naturally occurring
promoter CGIs that strongly initiate transcription in vivo may be
refractory to silencing mediated by elongating transcription passing
through them? We addressed this by identifying and analyzing
434 pairs of promoters linked to alternative promoter CGIs within
the same gene (SI Appendix, Fig. S17). As a measure of transcrip-
tional initiation strength, we focused on the level of preinitiation
RNA polymerase II (Pol2) binding. We found that Pol2 binding
correlates positively with unmethylated and H3K4me3-enriched
promoters (ρ = −0.33, P < 0.001 and ρ = 0.64, P < 0.001, respec-
tively) and alternative promoter CGIs (ρ = −0.46, P < 0.001 and ρ =
0.73, P < 0.001, respectively). By contrast, it correlates negatively
with the presence of transcription traversing the CGI and H3K36me3
enrichment (promoter CGI: ρ = −0.14, P < 0.001 and alternative
promoter CGIs: ρ = −0.28, P < 0.001) (SI Appendix, Fig. S13). We
calculated the differences in Pol2 binding between promoter CGIs.
We then linked alternative promoter CGIs in each pair and sorted
by the calculated difference in Pol2 binding the level of DNA
methylation; RNA expression; and enrichment in H3K36me3,
Pol2, H3K4me3, and H3K27me3 at the two linked promoters (SI
Appendix, Fig. S17). We found that the promoter CGI is hypo-
methylated regardless of gene expression. This is in contrast to the
alternative promoter CGI, which is more likely methylated,
H3K36me3-enriched, and transcribed through when the level of
the Pol2 is higher at the upstream promoter CGI (SI Appendix, Figs.
S17 and S18, group 1). Importantly, however, alternative promoter
CGIs with higher Pol2 binding than on the paired promoter CGIs
retain an unmethylated state, H3K4me3 enrichment, and lack
H3K36me3 (SI Appendix, Figs. S17 and S18, group 3).
Therefore, transcription is not sufficient to drive DNA methyl-
ation of a transcribed alternative promoter CGI, and whether or not
the latter becomes methylated depends on the activity of the pro-
moter CGI relative to that of the promoter CGI driving transcription
through it. Alternative promoter CGIs that are active (i.e., have a
higher enrichment in Pol2 than the paired upstream promoter CGI)
are protected from transcription-mediated methylation. Put simply,
there appears to be a “duel” between competing CGIs within a tran-
scription unit. These findings are consistent with observations made
at the individual loci tested in mES cells and provide an explanation
for why some intragenic CGIs, such as ACTB CGI, are able to
escape transcription-mediated silencing and methylation.
Discussion
This study shows how transcription of CGIs, either as normal
components of transcriptional units or when incorporated into ab-
normal transcriptional units as a result of chromosomal rearrange-
ments, frequently leads to their methylation. We have shown that
transcription through a CGI leads to the modification of its histones
by H3K36me3 and results in DNMT3B-dependent DNA methyl-
ation and modification by H3K9me3. Given that H3K36me3 has
been shown to act as a docking site for DNMT3B (19), it can be
implied that, together, these modifications repress the default ac-
tivity of intragenic CGIs to act as transcriptional promoters. This is
also consistent with other studies supporting a role for transcription
in regulating the activity of alternative promoters (30, 31). However,
future work will be needed to determine if the chromatin marks are
functionally involved in transcription-mediated silencing of CGIs
(e.g., by deleting histone methyltransferases, such as SetD2 or the
PWWP domain of DNMT3B).
Our findings are in agreement with recently published observa-
tions showing that de novo methylation of gene bodies requires
transcription (19). However, we find two major differences when we
compare the behavior of transcribed CGIs with that of gene body
regions. First, in contrast to surrounding gene body sequences,
CGIs that are traversed by transcription elongation remain unme-
thylated in naive mES cells and only become de novo-methylated
upon mES differentiation to EBs (Figs. 3 and 6). A similar de-
velopmentally dependent establishment of CGI methylation in the
presence of transcription has been observed in specialized situa-
tions, such as imprinting and X-inactivation (32, 33). This is prob-
ably due to the fact that in mES cells, CGIs are normally bound by
CpG binding factors like CFP1, a component of the Set1 complex
(34) that mediates trimethylation of H3K4 (26), a mark known
to prevent recruitment of de novo DNMTs (35). Consistent with our
findings, in mature oocytes, DNA methylation has been reported
to be present preferentially at CGIs located within active transcrip-
tion units (36), to be regulated by transcription (37), and to occur
following loss in H3K4me3 and increase in H3K36me3 (38). More-
over, a new report has now shown that transient transcription in the
early embryo leads to de novo methylation by altering histone pro-
files with functional consequences in later adult phenotypes (39),
further supporting the observed correlation between histone marks
and transcription-mediated de novo methylation of intragenic CGIs.
Second, unlike gene bodies, not all CGIs are susceptible to
transcription-mediated DNA methylation (Fig. 4 and SI Appendix,
Fig. 8. Transcribed intragenic CGIs are enriched in H3K36me3 and hyper-
methylated in hES cells genome-wide. (A) Classification of CGIs into promoter,
intragenic, and intergenic based on their genomic location. The promoter CGIs
were subclassified into promoter only, alternative promoter CGIs (CGI that acts
as a promoter CGI for one isoform of a gene and as an intragenic CGI for an-
other isoform of the same gene), and CGIs that cover the whole gene sequence.
(B) High DNA methylation level at intragenic CGIs strongly correlates with
H3K36me3 and anticorrelates with H3K4me3 in hES cells. The Spearman cor-
relation coefficient is shown. (C) Hypermethylated intragenic CGIs are over-
lapped by transcripts and enriched in H3K36me3 in hES cells genome-wide.
Each line in the pileup plot represents one CGI (±2 kb from the middle of
the CGI) sorted in descending order based on the DNA methylation levels (in
black). Plots from hES cells show the read distribution of H3K36me3 (green),
RNA expression (red), H3K4me3 (blue), and H3K27me3 (purple), while the DNA
methylation status of individual CpGs from BS-Seq data is plotted in black.
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Fig. S17), indicating that transcription, per se, is not sufficient to
drive methylation of intragenic CGIs. Our data show that the rel-
ative strengths of transcription initiation from the intragenic CGI
and the promoter of the gene within which it lies also play an im-
portant role in determining the status of the intragenic CGI. An
intragenic CGI, which itself acts as a strong initiator of transcription,
will not necessarily be silenced by elongating transcripts from a
linked, but weaker, CGI promoter.
The data presented here, together with previously published
evidence (19, 26, 40), support a model by which DNAmethylation is
established at intragenic CGIs (Fig. 9). Early during development,
both promoter and intragenic CGIs are unmethylated and
H3K4me3-enriched. The presence of H3K4me3 prevents methyl-
ation of the CGIs despite the presence of low levels of H3K36me3
(Fig. 9, Upper). Upon differentiation, at susceptible intragenic CGIs,
loss of H3K4me3 is correlated with an increased level of H3K36me3
deposited by the elongating Pol2/SETD2 complex. DNMT3B in a
complex with H3K9 methyltransferase is then recruited to intra-
genic CGIs via H3K36me3 and leads to their silencing via de novo
DNA methylation and trimethylation of H3K9 (22) (Fig. 9, Lower
Right). However, at highly active CGIs, H3K4me3 is retained and
is associated with loss of H3K36me3, resulting in the CGI re-
maining free of methylation (Fig. 9, Lower Left).
This model highlights a mechanism whereby the act of tran-
scription is primarily responsible for intragenic CGI methylation.
Nevertheless, the context and nature of the CGI itself are both
important in controlling whether a specific intragenic CGI is
likely to become methylated. This model may explain other
instances of aberrant CGI methylation observed in inherited dis-
eases, in which transcription has been implicated (9, 41). In addi-
tion, the model is compatible with some instances of aberrant CGI
methylation observed in acquired diseases, such as cancer. Indeed,
silencing of the p15 tumor suppressor in leukemia has also been
associated with up-regulation of antisense RNA transcription and
consequent promoter CGI hypermethylation correlated with a loss
of positive H3K4me3 and a gain of repressive H3K9me3 histone
marks (42). Moreover, we have reported that in sporadic cases of
colorectal cancer, transcription through the metastasis suppressor
gene TFPI-2 driven by an aberrantly active long interspersed element-
1 promoter is associated with epigenetic silencing of its promoter CGI
(43). Finally, based on the model, it is feasible that the switch to
maintenance of methylation at intragenic CGIs in somatic cells could
depend on the H3K9me3-mediated recruitment of the UHRF1/
DNMT1/proliferating cell nuclear antigen complex (44), providing
a potential way in which the RHBDF1’s intragenic CGI remains
methylated in tissues in which RHBDF1 is not expressed.
In summary, we have shown that the methylation status of a large
proportion of the 30,000 CGIs is primarily determined by tran-
scription. Silencing of intragenic CGIs by transcription-mediated
DNA methylation will reduce transcriptional noise from CGIs that
would otherwise initiate transcription from within the gene. Although
this applies to the majority of intragenic CGIs, a proportion of in-
tragenic CGIs with a strong propensity for transcriptional initiation
themselves are not silenced despite being transcribed. Presumably a
proportion of these remain active to subserve important bio-
logical functions. Finally, transcription-mediated DNA methy-
lation and silencing clearly represents an epigenetic mutational
process in a wide range of acquired diseases, including cancer, al-
though its contribution to such diseases is, as yet, poorly documented.
Materials and Methods
Constructs. The ZFαAS-STOP construct was generated by blunt-end cloning
the β-globin terminator from the βΔ5-7 plasmid (17) into a unique restriction
site at the junction between HBA2 and LUC7L fragments in the pZFαAS
plasmid (10). The MYOD-AS, UBC-AS, and ACTB-AS constructs were assem-
bled by cloning the PCR-amplified full length of MYOD1, UBC, and ACTB
into the pZERO-LUC7L plasmid in the place of HBA2 gene. The assembled
vectors were assessed by restriction digest and sequencing. Primers used are
listed in SI Appendix, Table S1.
Cell Culture. EBV-transformed lymphocytes, MEL cells, and mES clones were
cultured and differentiated as described (10). Stable mES clones carrying the
ZFαAS-STOP, MYOD1-AS, UBC-AS, and ACTB-AS clones were obtained by
coelectroporation of 1.2 × 107 ES cells with 50 μg of purified construct and
2 μg of a 1.8-kb fragment of the pPNT plasmid containing the geneticin
Fig. 9. Model for establishment of epigenetic si-
lencing at intragenic CGIs. (Upper) In ES cells, CGIs
found within the body of transcribed genes are free
of methylation and marked by H3K4me3, despite
the presence of a low level of H3K36me3. The
hypomethylated state of CGIs is maintained through
binding of ZF-CxxC domain-containing proteins,
including SETD1; histone H3K4 methyltransferase
(H3K4MT) complex (26); and KDM2A, an H3K36
demethylase enzyme (58). H3K4me3 is known to
inhibit DNMT3B binding to CGIs (35). Therefore, in
mES cells, DNA methylation and H3K9me3 are
found only within the non-CGI part of the tran-
scribed gene body (19, 40), but are omitted from
the intragenic CGI. (Lower Right) Establishment of
epigenetic silencing at the intragenic CGI occurs
upon developmental progression or in vitro dif-
ferentiation of ES cells to EBs. It is associated with
loss of H3K4me3 at the intragenic CGI and a fur-
ther increase in H3K36me3 probably mediated
by raised levels of transcription (thick bent
arrow). DNMT3B in complex with an H3K9 meth-
yltransferase (H3K9MT) is now able to bind to the
intragenic CGI, leading to establishment of DNA
methylation and H3K9me3 within it. (Lower Left)
In contrast, transcriptionally active intragenic
CGIs with an expression level higher than the
upstream promoter are refractory to DNA meth-
ylation and epigenetic silencing. These CGIs re-
main H3K4me3-enriched and transcriptionally active. (Upper and Lower Left) Double arrow at the intragenic CGI in indicates that the direction of
transcription from the intragenic CGI is not important.
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(G418) resistance gene. G418-resistant colonies were then selected and an-
alyzed by PCR and Southern blotting for construct incorporation. Stable
Dnmt3b−/− mES clones carrying the ZFαAS construct were similarly obtained,
except that a fragment carrying the blasticidin resistance gene was used for
cotransfection. Sequential selection, culture, and differentiation were car-
ried out according to published protocols (21, 45).
E14-TG2a.IV mES cells with an RMCE cassette (frt/Hprt−Δ3′/loxP/MC1neo/
lox511) in the mouse α-globin locus (25) were cultured and differentiated as
previously described (25, 46, 47).
H1 hES cells were expanded in mTeSR1 medium (Stem Cell Technologies)
on Matrigel.
Recombinase-Mediated Cassette Exchange. Test DNA sequences were amplified
fromhumangenomic DNAand cloned into themultiple cloning sites (MCSs) in the
RMCE donor vector (loxP/Hprt−Δ5′/frt/MCS/lox511) (25). Primers used are listed in SI
Appendix, Table S2. The in vitro-methylated version of the RHBDF1’s intragenic
CGI was obtained by incubating the modified RMCE donor vector with M.SssI
enzyme in the presence of S-adenosyl-L-methionine. The efficiency of the reaction
was assessed by digesting the purified vector with DNAmethylation-sensitive and
-insensitive restriction enzymes. The targeting of the RMCE donor vector to E14-
TG2a.IV mES cells with an RMCE cassette in the mouse α-globin locus was per-
formed as described by Lynch et al. (25) and verified by Southern blot analysis.
Recombineering Strategy Called Bacterial Artificial Chromosome Shaving. The
RMCE donor vectors containing the gene sequence of RHBDF1, including its
promoter (RHBDF1+P; chr16:47,861–63,210, hg18) and minus its promoter
(RHBDF1−P; chr16:47,911–60,819, hg18), were engineered using a λ-Red–
mediated recombineering strategy called bacterial artificial chromosome
(BAC) shaving. The human BAC clone, CTD3077J14 (Life Technologies), was
modified by replacing BAC sequence between the 3′ end of the RHDBF1+
P/−P gene sequence and the BAC origin of replication with the elements of
the RMCE donor vector and a selection cassette, PGK-Tn903hyg-loxP/Hprt−
Δ5′/frt/. Next, the sequence upstream of the RHBDF1 gene up to the BAC
origin of replication was replaced with the cassette lox511-PGK-Tn903neo.
Finally, an additional recombineering step was carried out to retrieve the
Tn903hyg-loxP/Hprt−Δ5′/frt/RHDBF1+P/−P/lox511-PGK-Tn903neo sequence
from the shaved BAC into a minimal p15 plasmid vector by gap repair.
Individual recombineering steps were assessed by antibiotic selection, PCR
amplification to sequence the recombined junctions and determine BAC
coverage, and restriction digestions.
ChIP and ChIP-Sequencing. ChIPwas performedwith theMillipore ChIP Assay Kit
(17-295; Millipore). Briefly, 1 × 107 cells were cross-linked with 1% formalde-
hyde for 10 min. Chromatin was prepared according to the Millipore instruc-
tions and sonicated to an average fragment size of 500–1,000 bp using a
Diagenode Bioruptor. Fragmented chromatin was immunoprecipitated with
antibodies raised against H3K4me3 (ab8580; Abcam), H3K36me3 (ab9050;
Abcam), H3K9me3 (kindly donated by Thomas Jenuwein, Max Planck Institute
of Immunobiology and Epigenetics, Freiburg, Germany; 17-625, Millipore; and
pAb-056-050, Diagenode), H3K27me3 (17-622; Millipore and pAb-069-050;
Diagenode), H3 (ab1791; Abcam), and IgG (X0903, Dako; used as a control).
Precipitated DNA was analyzed by real-time PCR using SYBR Green chemistry
except for the amplicon along the HBA locus (probes 5–9 in Fig. 1A), for which
TaqMan chemistry was used. Primers used are listed in SI Appendix, Table S3.
H3K36me3-immunoprecipitated chromatin from H1 hES cells was pre-
pared as described above. ChiP-sequencing (ChIP-Seq) libraries were prepared
using the NEBNext Ultra DNA Library Prep Kit for Illumina (E7370S; New
England BioLabs) and sequenced on a NextSeq 500 sequencing system. The
ChIP-Seq data were analyzed using an in-house pipeline that automatically
assesses the quality of data, trims adaptors, merges short reads, maps reads to
the reference genome (hg19), filters data for duplicates, and performs peak
calling. The data were visualized in the UCSC Genome Browser.
RT-PCR. RNA was isolated using TRI Reagent (T9424; Sigma–Aldrich) and
subsequently DNase-treated using a DNA-free DNA Removal Kit (AM1906;
Ambion). The expression analysis of constructs in the ZF model was per-
formed using the Roche Expand reverse transcriptase kit (11785826001)
following the manufacturer’s guidelines. Gene-specific primers or random
primers (C118A; Promega) were used depending on whether strand-specific
analysis was required. Expression of strand-specific RNA was performed
using end-point PCR, while expression of spliced sense genes was analyzed
by real-time PCR using SYBR Green chemistry and expressed relative to
mouse Aprt. For the experiments on RHBDF1, first-strand cDNA was syn-
thesized from total RNA using a SuperScript III First-Strand Synthesis
SuperMix for qRT-PCR kit (11752-050; Invitrogen) and quantified by real-
time PCR using SYBR Green chemistry. The gene expression was normalized
to mouse Rm18s. Primer sequences are listed in SI Appendix, Tables S4
and S5.
Bisulfite Sequencing. Genomic DNA was bisulfite-converted using the EZ DNA
Methylation-Gold kit (D5005; ZymoResearch). Enzymaticallymethylated human
male genomic DNAwas used as amethylated control (S41821;Millipore). Several
nested primer sets were designed to cover the region of interest (SI Appendix,
Table S6). The amplified bisulfite-modified DNA was purified to remove the
primer dimers. Samples were pooled together, and sequence libraries were
generated using a NEBNext Ultra DNA Library Prep Kit for Illumina (E7370S;
New England BioLabs), to sequence on MiSeq (Illumina). The bisulfite se-
quencing data were aligned to hg18 and mm9 using Bismark (48) and Seq-
Monk tools, and then visualized in the UCSC Genome Browser.
For the ZFαAS time course, amplified products were cloned, sequenced,
and analyzed as described by Vafadar-Isfahani et al. (49).
CapSeq. Total RNA was extracted using TRI Reagent (T9424; Sigma–Aldrich)
and then fragmented using the NEBNext Magnesium RNA Fragmentation
Module (New England BioLabs). Fragmented RNA was cleaned up using the
RiboMinus Concentration Module (Life Technologies), and the 3′ adapters
were ligated using a modified version of the NEBNext Small RNA Library
Prep Set for Illumina (Multiplex Compatible) (New England BioLabs). Sam-
ples were subjected to a second round of cleanup using the RiboMinus
Concentration Module, and then subsequently treated with calf intestinal
phosphatase and tobacco acid phosphatase. The reaction was cleaned up
using the RiboMinus Concentration Module as before, and annealing of the
small RNA reverse transcription primer and ligation of the 5′ adapter were
performed. Reverse transcription was carried out using the SuperScript III First-
Strand Synthesis system, followed by library amplification, and was cleaned up
using a QIAquick PCR Purification kit (28104; Qiagen). Samples were se-
quenced on the NextSeq 500 sequencing system. CapSeq data were aligned to
build hg19 using STAR and visualized in the USCS Genome Browser.
5′ RACE. A 5′ RACE assay was performed on total DNase-treated RNA using
the 5′ RACE System for Rapid Amplification of cDNA Ends (18374-058; Invi-
trogen). Briefly, first-strand cDNA was synthesized using strand-specific pri-
mers to hRHBDF1, andmGapdhwas used as an internal control. Actinomycin
D was added to prevent second-strand cDNA synthesis. The cDNA was then
cleaned up using a S.N.A.P. column (Invitrogen), TdT tailing was performed,
and the dC-tailed cDNA was amplified using nested strand-specific hRHBDF1
and mGapdh primers in combination with the provided abridged anchor
primer. Following amplification, the cDNA was quantified by real-time PCR
using SYBR Green chemistry. Gene expression was normalized to mouse
Gapdh. Primer sequences are listed in SI Appendix, Table S7.
Small RNA Northern Blots. Total RNA was run on a polyacrylamide gel, trans-
ferred to a nylon membrane, and hybridized with oligonucleotide probes to
detect small RNA species of HBA2 in accordance with published techniques
(50). An oligonucleotide complementary to microRNA miR16 (5′ CGCCAA-
TATTTACGTGCTGCTA 3′) was used as a positive control, as previously reported,
to be expressed at low levels in mES cells and higher levels in EBs (51, 52).
Small RNA-Seq. Total RNA was extracted using a Qiagen AllPrep kit using the
conditions indicated for enrichment in small RNAs. Libraries were prepared
according to the NEBNextMultiplex Small RNA Library Prep Set for Illumina (New
EnglandBioLabs) and sequencedonaHiSeq system. The small RNA-Seqdatawere
trimmedwith an in-house Perl script to 25-base-long reads to remove sequencing
adaptors. Reads were mapped to both mm9 and hg19 genomes using STAR
(allowing each pair to map a maximum of two times to the genome). Read pairs
per million mapped read pairs were calculated within the elements of the ZFαAS
constructs [HS-40 enhancer (chr16:163249–164691), HBA2 gene (chr16:222845–
223709), part of LUC7L gene (chr16:277024–282124)], and miR16 as a positive
control (chr14:62250772–62250794 and chr3:68813839–68813861) using sam-
tools. Reads that mapped to hg19 and mm9 within the ZFαAS constructs were
filtered out using an in-house Perl script (only a few double-mapped reads
were reported). The data were expressed as reads per million normalized to
mouse mapped reads and visualized in UCSC using bedtools and ucsctools.
Bioinformatics Analyses. Annotated CGIs (n = 27,718, UCSC definition, hg19)
were classified into promoter, intragenic, and intergenic based on their
genomic location. CGIs were classified as promoter-associated (n = 13,478) if
they overlap TSS ± 100 bp of USCS-annotated genes. CGIs were classified as
intragenic-associated (n = 8,795) if they overlap a gene sequence lacking
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promoter CGI ± 100 bp and also were not already categorized as promoter
CGI, while the remaining CGIs were cataloged as intergenic-associated (n =
5,445). Sequentially, the promoter CGIs were classified into (i) promoter CGIs
that overlap the whole gene sequence (n = 413), (ii) alternative promoter
CGIs that overlap TSS ± 100 bp and gene body sequence (n = 2,836), and (iii)
promoter-only CGIs (n = 10,229). Data from each step of the analysis were
visually inspected using MIG. Heat map plots for promoter and intragenic
CGIs in hES H1 cells were generated for CGIs with >60% coverage using
datasets either publicly available [bisulfite sequencing (BS-Seq) (GSM429322)
(53), RNA-Seq (GSM958733) (54), H3K4me3 (GSM733657), H3K27me3 (GSM733748),
Pol2 MMS-126R (GSM803366), input control for H3K4me3 and H3K27me3
(GSM733770), Pol2 (GSM803364)] or generated in-house (H3K36me3). The
input was subtracted from the ChIP data. CGIs were sorted in descending
order based on the DNA methylation level or differential Pol2 binding
within ±2 kb from the middle of CGI, and enrichment for H3K36me3,
RNA expression, H3K4me3, and H3K27me3 reads was displayed using the
in-house Perl script and visualized in R. Other publically available data-
sets used to determine RHBDF1 DNA methylation levels and expression
were as follows: Bio-CAP-Seq: testes (GSM1064675), liver (GSM1064676),
input control (GSM1064674) (55); BS-Seq: hES (GSM429322); and RNA-
Seq: hES (GSM958733), liver (GSM752705) (56). RNA-Seq, ChIP-Seq, and
CAP-Seq datasets produced in the course of this study have been sub-
mitted to the Gene Expression Omnibus with superseries accession no.
GSE84355.
Motif enrichment was conducted using Homer v4.9 (57).
Statistical Analyses. Statistical significance was calculated by a two-tailed
t test using Graphpad Prism 6, R, or Excel on data obtained by analyzing
in triplicate a minimum of two biological replicates.
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2Supporting Tables
Table S1 - Sequences of primers used to PCR amplify the MYOD1, UBC and ACTB human genes.
Primer name: For (5’-3’) Rev (5’-3’)
MYOD1 TACTGTGTGACTGCCACTGTGATG TTCTATGGCGTTCCCCTGCTAC
UBC TTTTTCTCTGGGAGTGACCATACG TGTAGAGAAACATCAGACACCTGCG
ACTB GAGTGTGGTCCTGCGACTTCTAAG CCTCTAAGGCTGCTCAATGTCAAG
Table S2 - Sequences of primers used to PCR amplify DNA fragments targeted to RMCE mES cells.
Primer name: For (5’-3’) Rev (5’-3’)
HBA2 promoter CGI ACAGAGATCTCGTCCGGGTGCGCGCATTCCTC ACAGGCGGCCGCCGGCCCAGGCCCGCAGCCGC
RHBDF1 intragenic CGI AGACAGATCTGATGAGGAGGAATGAATATG AGACAGATCTCCTGACTCCAGCATCTCCTC
Table S3 - Sequences of primers used for ChIP analysis.
Primer name: For (5’-3’) Rev (5’-3’) Taqman probe (5’FAM- 3’TAMRA)
5’ HBA
5’ to HBA2 CGI) AAGTCTTCCATCAGATAGCATTTGG GTCATGGACTCACAGTTTGTGTGA TGTCACAGTGGAACCACGACCTCTAGGCC
HBA-CGI
(HBA2 promoter) GGGCCGGCACTCTTCTG GGCCTTGACGTTGGTCTTGT CCCACAGACTCAGAGAGAACCCACCATG
HBA-ex3
(HBA2 exon 3) GGGCCGGCACTCTTCTG GGCCTTGACGTTGGTCTTGT CCCACAGACTCAGAGAGAACCCACCATG
LUC7L-body
(gene body) CCACGATGGCATAAGGATAATCT CATACTTTCCGTGCCCTTGTG CGTGCTCTCTCATCCACACTGGGTATGG
LUC7L-prom
(promoter) GTTCCCCTTGCAATGGTACAG GCTCCTTGGGAAGAAGCTACAC TTTTCGAGGCCCATCCGGCTC
mActb
(promoter) CGGTGTGGGCATTTGATGA CGTCTGGTTCCCAATACTGTGTAC AAGATGGACCTAATACGGCTTTTAACACCCG
hACTB
(promoter) CGGCCAACGCCAAAACT CCCTCTCCCCTCCTTTTGC TCCCTCCTCCTCTTCCTCAATCTCGC
3hRHBDF1
(promoter) GAGATGCTGGAGTCAGGACCAT AGGAGTCAGGAGCAGCAGTCA TCCTAGCTCACCCAGAGGCACAGAGG
h18S 18S rRNA control kit, Eurogentec, Liege, Belgium
mPolrmt
(gene body) CCGTGGCACGCATTAGTTT CTGGACGTCGCTGCATTCT NA
mPcdh8
(promoter) TGCACCAGGCGGAACTGT TGCTGGCCTTCGATGTTGT NA
hACTBp1
(promoter) AAGACTCCATGTGCCACAGA GGCAAGAAAGGGTGACAAGG NA
hACTBgb2
(intragenic sequence) CTTGGGATGGGGAGTCTGTT ACTAACACTGGCTCGTGTGA NA
hMYOD1-1
(promoter) TGTGGAAACGTGCAGATTTAGATG GCGCCAATCTCTCCAAACTC NA
hMYOD1-2
(intragenic sequence) CCCTCCCAACAGCGCTTTA CAGTTCTCCCGCCTCTCCTA NA
hUBC-1
(promoter) TTTCCATGCCTCCCTGTTG TGTACATTCTGAGGGCCAGGTA NA
hUBC-2
(intragenic sequence) GTGAAGTTTGTCACTGACTGGAGAA CGGCACCGCCATAACTG NA
MmjSat (mouse major
satellites) GACGACTTGAAAAATGACGAAATC CATATTCCAGGTCCTTCAGTGTGC NA
mActb
(promoter) AAGGAGCTGCAAAGAAGCTG CCGAAAGTTGCCTTTTATGG NA
mGapdh
(promoter) GATTACGGGATGGGTCTGAA GCTGCACCTCTGGTAACTCC NA
mNprl3.1
(gene body) GTTGTCTGCAGGGAGGAGAG CCATTAGGGCCAGATCAGAA NA
mNprl3.2
(gene body) CCCCTTTCCCACTCAGTCAT GCTATCCTCAATGTGCCTGC NA
mCcna2
(gene body) ACCCCCAAACTGGACTTACC CTTGGCTGCACCAACAGTAA NA
mIG1
(3ntergenic region) TACCCAGACACACACCTCCA CACATGCCATTGTGTGTGAA NA
mIG3
(intergenic region) ACATTGTGCAGGGTGTTGAA GGAAAAATCTGCCAGGATGA NA
hRHBDF1.1 (promoter
CGI) GGAGTTTCAGCTCGGAGACA CCCCAGGTTCCTCTGAACTC NA
hRHBDF1.2 (intragenic
sequence) GGCACTGAGTCCAGAGAAGG CGTAAGCACCTGCTGTCTGA NA
hRHBDF1.3 (intragenic
CGI) GAACGGGGACACACTGACTT GTGGAATGGGACAGCAATCT NA
4hRHBDF1.4 (intragenic
sequence) TGGTTGGGGTAGCTGTAAGG TCCTCGGTCCCAATATGCTC NA
Table S4 – Sequences of primers used for strand specific RT
Primer name: Primer Sequence (5’-3’)
hHBA2 TGGAGGGTGGAGACGTCCTG
hMYOD1 TGATTTCTACAGCCGCTCTACCC
hUBC TCAGCAGAAGGACATTTTAGGACG
hACTB TGCTTTCAGGGCAGTTGCTC
mAPRT GGTAGCTCACAAAGGTCACT
Table S5 – Sequences of primers used to screen for PCR of RTs
Primer name: For (5’-3’) Rev (5’-3)
hHBA2-AS GAAGGACAGGAACATCCTGCG CCGCGCCCCAAGCATAAACCC
hMYOD1-AS GGGTGTTGGAGAGGTTTGGAAAGGGC ACACTGCGGGGCGGGGCTTG
hUBC-AS CCCACCTTGTTTCAACGACCTC TAGTCCCTTCTCGGCGATTCTG
hACTB-AS AGTGCCCAAGAGATGTCCACA AAAAGAGCGAGAGCGAGATTGAG
hMYOD1 CGGCGGAACTGCTACGAAG AGGCGACTCAGAAGGCACG
mMyod CGGCGGCAGAATGGCTAC CGCATTGGGGTTTGAGCC
hUBC TTGGGTCGCAGTTCTTGTTTG AGGGATGCCTTCCTTATCTTGG
mUbc GCAAGACCATCACCCTGGACG CACCCAAGAACAAGCACAAGGAG
mActb GGGGGGACAAAAAAAAGGGAG CGGGGAAGGTGACAGCATTG
mAprt GGAAATCCAGAAAGATGCCT TCTAGCCAGCTCCTCAGTCA
mHba1/2 CTGGGGAAGACAAAAGCAAC GCCGTGGCTTACATCAAAGT
5mRm18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
mNanog CCAAAGGATGAAGTGCAAGC GTGCTGAGCCCTTCTGAATC
mOct4 GGCGTTCTCTTTGGAAAGGTGTTC CTCGAACCACATCCTTCTCT
hRHBDF1 (nascent) TGACTGTTCCTGCTTGCATC GGGTCCCTAATCTGGGGTAA
Table S6 - Sequences of primers used for bisulphite analysis.
hRHBDF1’s intragenic
CGI in RMCE mES and
hES
1a GATGAGGAGGAATGAATATG CCAACCTCCCAAATACTA
1b TGAATATGATAAGGTTTTG AAAACCCTCATCCACCTA
2a AATGAAGTTGTGTATTTG CTTCACCTACTAACTTACC
2b TAGGTGGATGAGGGTTTT ATAAACCCCTATACCTTC
3a TGGGTTTAGGGAAGGTATAG ACAAAAAATAATAAACAC
3b GAAGGTATAGGGGTTTAT TATAAACTAAACATAATAAA
4a GGAGTTTTTATTTTAATTTAGGTTTTGTTTGTTA TTCCAACTCCCTACCATCCC
4b TTATTATGTTTAGTTTATA CAATATTACTTTTTTACTAACA
5a GGTATTAGGGTATTTTGT CAACCACCTAATACTATA
5b TGTTAGTAAAAAAGTAATATTG CACCTAATACTATAAATA
6a TATTTATAGTATTAGGTG AATCTCATACTCACTTCCC
6b TATAGTATTAGGTGGTTG AAACTTCACTCCAACTAACTTTCT
7a GGGAAATTAGTTGTGTTT CCTAACTCCAACATCTCCTC
7b AGAAAGTTAGTTGGAGTGAAGTTT CAAATCATAAACCCCCTAACC
hRHBDF1’s promoter
CGI in RMCE mES and
hES
1a GTTTGGTTGTTATTTTAGT AACTTTTCTTCCTAAAATTTC
1b TATAGAGTGAGAGTTTGT CCAACAACTAAAAATCCCA
2a GAGTTTAGAGGAATTTGGGGTAT CTCAAAACCCCCCAAAAC
2b TGGGATTTTTAGTTGTTGG CTCAAAACCCCCCAAAAC
6hRHBDF1’s promoter
CGI in RMCE mES
3a GTTTTGGGGGGTTTTGAG ACAACTCAAACCTCAATCT
3b GTTTTGGGGGGTTTTGAG CAAACCTCAATCTAAAACC
hRHBDF1’s promoter
CGI in RMCE hES
3a GTTTTGGGGGGTTTTGAG CAAACCTCAATCTAAAACC
3b GTTTTGGGGGGTTTTGAG ACTCAAACCTCAATCTAAAACC
hHBA2’s promoter CGI
in RMCE mES and hES
1a TGTATTTTTAGGGGAGGT TAAAAAAAAACAAAAACATCCTA
1b TGTATTTTTAGGGGAGGT ATTAAAAATAACCTATAAATC
hHBA2’s promoter CGI
in RMCE mES
2a GAGGTTTTGGAGAGGTGA AATCTACTTTCCCATATC
2b GATTTATAGGTTATTTTTAAT TAATCCTCTACCCTAAAA
hHBA2’s promoter CGI
in hES
2a GAGGTTTTGGAGAGGTGA AATCACCAACAAACAATAAC
2b GATTTATAGGTTATTTTTAAT TAATCCTCTACCCTAAAA
HBA2 CGI in ZFAS
mES cells
1a TGGAGAGTAGGAGGGGTTTTG CAAAAAACAACACCATAATAAATTCTCTCT
1b TTTTTGAGTTTTTATGGGTTAGGG CCATAATAAATTCTCTCTAAATCTATAA
MYOD 1a GTTTATTGTGGGTTTGTAAG CTACCCCAATAACAACTACC
1b GAGTAAAGTAAATGAGGT ATCCTAACCCAAACCTCC
UBC 1a GTGATTTAAAAATAAAGAT CCTAAAATCACCCAAATC
1b GGTTAGGAGGGAGGGGAG CTTCTACTAATACTAAAATTC
2a GAATTTTAGTATTAGTAGAAG CCAATTCAAAACAACCTTAC
2b GATTTGGGTGATTTTAGG AACCCAAACTACAACCCTTAA
ACTB 1a GAGGGGGTTGGGGTTTGG CTACCCCACCCAACCAACT
1b GTTTGTTTTTTATGGTAATAA CTCCCCTACCTAATACCTA
LUC7L
1a GTATATAGGAAGGAGGTTG CTAAACCAACTCATAAAC
1b GTTGAAGTTTTATTTATGG AACCCTACTAAACCAACTC
Table S7 - Sequences of strand-specific primers used for 5’RACE.
7Primer name: Strand-specific primer For (5’-3’) Rev (5’-3’)
hRHBDF1 GAGTCAGGAGCAGCAGTC CAGTGTCATCTGCCACACG TCCTGACTCCAGCATCTCCT
mGapdh GAGTTACCAGAGGTGCAG GTACGGGTCTAGGGATGCTG ATCACGTCCTCCATCATCCC
Table S8 - Sequences of primers used for Msp-PCR.
Primer name: For (5’-3’) Rev (5’-3’)
HBA2 CCGCGCCCCAAGCATAAACCC GAAGGACAGGAACATCCTGCG
MYOD1 GGGTGTTGGAGAGGTTTGGAAAGGGC TCGAAACACGGGTCGTCAT
UBC1 GAACAGGCGAGGAAAAGTAGTCC TTGGCGGTCTCTCCACACG
ACTB1 AGTGCCCAAGAGATGTCCACA AAAAGAGCGAGAGCGAGATTGAG
LUC7L1 CACCAAGGGTGACTTATAGAGCTGG GCAACTCTCTTTTTTAAGGGTGGG
LUC7L2 TCAGTTTACGGTTCCCCTTG GCTTCAGCCTCCTTCCTATG
Aprt CGI TCTTCCCCGACTTCCCAATC GAACAAGGACAGGAGAGTGACCC
Airn CGI ATTCTGGTTGTGCCGAGTTGCGAG CGTGGCACTTTTGAGTTCATCTCTC
8Supporting Figures
Figure S1. The ZF mouse ES system recapitulates the chromatin changes observed in ZF in vivo.
ChIP was performed using antibodies to H3K27me3 (A), H3K9me3 (B and D) and H3K4me3 (C), in ES cells
and in differentiated EBs (A and B), or in EBs differentiated towards cardiomyocyte lineage (C and D),
carrying the control ZFS or the ZFAS construct. The data were normalized to INPUT and are displayed
relative to the highest value. P values were calculated by t test: *=p<0.05; **=p<0.01; ***=p<0.001.
Pos=positive control (Actb promoter for H3K4me3; Polrmt gene body for H3K9me3; Pcdh8 CGI for
H3K27me3); Neg=negative control (intergenic region for H3K4me3; Actb promoter for H3K9me3 and
H3K27me3).
9Figure S2. Antisense-RNA transcription is required for the silencing of HBA2 in the ES model of ZF.
10
(A) Schematic diagram of the ZFAS-STOP construct: the -globin transcription terminator (17) (red box)
was introduced between HBA2 and LUC7L to stop transcription originating from LUC7L promoter. The
position of qPCR primer used for strand specific RT-PCR to test for transcripts through the HBA2 CGI is
indicated. (B) Ethidium bromide stained gel of strand specific RT-PCR to detect HBA2 CGI transcripts (AS)
in total RNA from two stable ZFAS-STOP clones representing those expressing low to undetectable (Y5)
and detectable (Y9) levels of AS, compared to ZFAS cells. Aprt =positive control. RT reactions were
performed with (+) or without (−) reverse transcriptase. (C) Southern blot of ES and derived EBs carrying
control ZFAS or ZFAS-STOP construct. Samples were digested with Pst1 alone (P) or in combination
with the methylation sensitive enzyme Eag1 (PE); and hybridized with a fragment encompassing the HBA2
gene (10) showing no (Y5) or intermediate (Y9) DNA methylation relative to ZFAS clones. (D) Expression
of HBA2 mRNA in ES and EBs from the ZFAS and ZFAS-STOP clones measured by real time RT-PCR and
expressed relative to Aprt control. (E) ChIP was performed using antibodies to H3K4me3 and H3K9me3 in
ES and EB from ZFAS and ZFAS-STOP clone Y5. The data were normalized to INPUT and are displayed
relative to the highest value. Pos=positive control (Actb promoter for H3K4me3; Polrmt gene body for
H3K9me3); Neg=negative control (intergenic region for H3K4me3; Actb promoter for H3K9me3). (F) Small
RNA northern blots from ZFAS cells at different time points between day 0 and day 6 of differentiation
were hybridized with the HBA2 probe used in (C) showing no evidence of small RNAs. Membranes were
stripped and re-probed with the control miRNA miR16 that is expressed in both ES and EB. The ethidium
bromide staining membrane of is used as a loading control. (G) Small RNA-Seq from ZFAS cells at day 0,
day 2, day 4 and day 6 of differentiation were quantified at the elements of the ZFAS construct and the
positive control mouse micro-RNA miR16 and expressed as reads per million (RPM) per mouse mapped
reads. Error bars of +/- 10 reads were added to the plots to illustrate the absolute minimum read counts
needed to any quantitative analysis of the data.
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Figure S3. Profile of chromatin changes across HBA2 in differentiating ZFAS and 8bb3 cells.
(A) ChIP was performed using antibodies to H3K4me3, H3K9me3, H3K36me3 in undifferentiated ZFAS
cells and at different time points of in vitro differentiation. The data were normalized to INPUT and are
displayed relative to the highest value. Pos=positive control (Actb promoter for H3K4me3; Polrmt gene
body for H3K9me3; Ccna2 gene body for H3K36me3); Neg=negative control (intergenic region for
H3K4me3 and H3K36me3; Actb promoter for H3K9me3). (B) Southern blot of ES and derived EBs from J1-
1, 8bb2 and 8bb3 carrying ZFAS construct. Samples were digested with Pst1 alone (P) or in combination
with the methylation sensitive enzyme Eag1 (PE); and hybridized with a fragment encompassing the HBA2
gene. (C) Real time RT-PCR of Oct4 and Nanog mRNAs in ES and EB from clones J1-1, 8bb2 and 8bb3. The
data were normalised to Aprt expression. (D) ChIP was performed using antibodies to H3K4me3,
H3K9me3, H3K36me3 in undifferentiated 8bb3 ES and derived EBs carrying ZFAS construct. The data
were normalized to INPUT and are displayed relative to the highest value. Pos=positive control (Actb
promoter for H3K4me3; Major Satellites for H3K9me3; Ccna2 gene body for H3K36me3); Neg=negative
control (intergenic region for H3K4me3 and H3K36me3; Actb promoter for H3K9me3). *=p<0.05;
**=p<0.01; ***=p<0.001, t-test.
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Figure S4. DNA methylation at HBA2 CGI in ZFAS ES cells increases upon differentiation.
(A) Southern blot of ZFAS cells at day 0, 2, 3, 4, 5 and 6 of differentiation. Membranes of DNA samples
incubated with Pst1 (P) alone or in combination with the methylation sensitive enzyme Eag1 (PE), were
hybridised with a HBA2 probe (left panel), stripped and re-probed with a LUC7L CGI probe as a control for
complete digestion (middle panel) (10). Note that the LUC7L CGI probe cross-reacts with human (h) and
mouse (m) and they are both unmethylated. % methylation at the Eag1 site were calculated as the ratio
of methylated signal to total signal by densitometry (right panel). (B) Snap shot of UCSC web browser for
human genome assembly GRCh37/hg19 showing the 570bp region of the HBA2 CGI analysed by bisulfite
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sequencing (highlighted in blue) and the 307bp fragment amplified by Msp-PCR (grey box). The red dashed
line indicates the position of the Eag1 site tested by Southern blotting in A. Below this are shown the
lollipops diagrams summarising the results of the bisulfite sequencing at different time points of
differentiation; grey vertical bars indicate the CpGs associated with Msp1 sites. Data shown are the
average of two independent experiments for each time point. (C) Graph plotting the overall % methylation
at the different time points as assessed by bisulfite sequencing. (D) Left, schematic diagram of the
construct used to generate the ZFAS clone with indicated the fragments analysed by methylation
sensitive PCR. Right, gel image of the Msp-PCR analysis performed on Msp1 (M) and HpaII (H) digested
genomic DNA from undifferentiated (ES) and day 6 (EB) ZFAS cells. HBA2 is a 308bp fragment of the
HBA2 CGI including 4 Msp1 sites; LUC7L1 is 208bp fragment of LUC7L with no Msp1 sites; LUC7L2 is a
248bp fragment from LUC7L CGI with 3 Msp1 sites; Aprt CGI is a 164bp fragment from mouse Aprt
promoter CGI spanning 4 Msp1 sites; and Airn CGI is a 498bp fragment from the mouse Airn locus with 3
Msp1 sites (Primers are listed in Table S8). Airn CGI corresponds to the maternally imprinted mouse Igf2R
DMR2, known to be methylated in ES and differentiated cells (32). This region was used as a control for
methylation detection after HpaII digestion; LUC7L2 and Aprt CGI act as controls for complete HpaII
digestion as they are known to be unmethylated. - = no template control; + = genomic DNA positive
control.
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Figure S5. Not all CGIs become methylated when traversed by transcription driven by the LUC7L
promoter.
15
(A) Strand specific RT-PCR performed on total RNA from ES and EB carrying the MYOD1-AS, the UBC-AS
or the ACTB-AS constructs to study antisense RNA transcription originating from LUC7L promoter. cDNA
obtained with (+) or without (-) reverse transcriptase were used as templates; gDNA= genomic DNA
control. The Aprt primers span an intron, thus Aprt amplicon from gDNA is larger than that from cDNA.
Results are shown for one representative clone for each construct. (B) Expression of MYOD1, UBC and
ACTB mRNA in ES and EB measured by real time RT-PCR and expressed relative to Aprt control. (C - E)
Methylation sensitive PCR assay performed on DNA from ES and EBs obtained from MYOD1-AS (C), UBC-
AS (D), ACTB-AS (E) clones as described in the legend to Figure S4. Shown are the results for one
representative clone of the six analysed. +=gDNA; -=water control.
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Figure S6. The MYOD1 CGI is sensitive to transcription mediated methylation.
The DNA methylation status of the part of the promoter CGI of human MYOD1 (A) and LUC7L (B) was
analysed by sequencing of bisulfite converted DNA from MYOD-AS mES (track in light brown) and derived
EBs (track in dark brown) of one representative clone; and human methylated control genomic DNA (track
in black). Individual CpG coverage in bisulfite analyses is indicated below each DNA methylation track.
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Figure S7. The UBC CGI is sensitive to transcription mediated methylation.
The DNA methylation status of the part of the promoter CGI of human UBC (A) and LUC7L (B) was analysed
by sequencing of bisulfite converted DNA from UBC-AS mES (track in light navy blue) and derived EBs
(track in dark navy blue) of one representative clone; and methylated control human genomic DNA (track
in black). Individual CpG coverage in bisulfite analyses is indicated below each DNA methylation track.
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Figure S8. The ACTB CGI is not methylated by transcription driven by the LUC7L promoter.
The DNA methylation status of the part of the promoter CGI of human ACTB (A) and LUC7L (B) was
analysed by sequencing of bisulfite converted DNA from ACTB-AS mES (track in light blue) and derived EBs
(track in dark blue) of one representative clone. In vitro methylated human genomic DNA (track in black)
was used as a methylated control. Individual CpG coverage in bisulfite analyses is indicated below each
DNA methylation track.
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Figure S9. The RMCE system in the mouse alpha globin locus.
(A) Outline of the RMCE system established in the mouse alpha globin locus (25). The box outlined in red
indicates the region replaced by RMCE acceptor sequence to allow integration of defined DNA sequences
of interest with high efficiency into a single pre-defined genomic location in the mouse genome. (B) The
RMCE is located in the well-characterized alpha globin locus, which is transcriptionally silent, and lacks
both active (H3K4me1 and H3K4me3) and repressive (H3K27me3) histone marks in mES cells. In addition,
it is not in close vicinity to CGIs (26 and 44kb away), suggesting that it represents a relatively neutral
chromatin environment.
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Figure S10. The RMCE system established in the mouse alpha globin locus does not affect the DNA
methylation status of the integrated sequences.
The DNA methylation status of the sequence encoding the naturally methylated C16ORF35’s intergenic
region (A) and the HBA2 promoter CGI (B) targeted into the established RMCE system was analysed by
sequencing of bisulfite converted DNA. Shown are the DNA methylation analysis in hES cells (track in red),
in three targeted RMCE-derived mES clones (tracks in blue and green), and methylated control genomic
DNA (track in black). Individual CpG coverage in bisulphite analyses is indicated below each DNA
methylation track.
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Figure S11. RHBDF1 with (+P) and without (-P) promoter in the RMCE system.
(A) Sequence of human RHBDF1 with and without the promoter used to generate the RMCE donor vector
is marked by light and dark pink, respectively. Publicly available ChIP-Seq and DHS-Seq data from hES cells
(ENCODE and Bernstein, Broad Institute) were plotted for RHBDF1. (B) The nascent transcript levels of the
human RHBDF1+P/-P construct in RMCE mES clones. The results are indicated as the mean value ± s.d. of
at least three independent experiments.
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Figure S12. The intragenic CGI in the context of RHBDF1-P acts like a promoter CGI.
(A and B) ChIP was performed using antibodies to H3K4me3 (A), H3K36me3 (B) and H3 or a control non-
specific IgG antibody, in mES and day 7 EBs carrying the intragenic CGI in the context of RHBDF1-P. DNA
fragments amplified are shown in Fig. 1A. Positive controls: the promoter of mouse Gapdh and Actb (A);
the gene body sequence of mouse Nprl3 and Ccna2 (B) and negative controls: the gene body sequence of
mouse Nprl3 and Ccna2 (A); two intergenic sites (B). The data were normalized to INPUT and the H3 level,
and are displayed as an average ± s.d. of three independent experiments relative to the highest value.
Paired t test was used to calculate statistical significance: *= p<0.05; **=p<0.01. (C) The intragenic CGI
gave rise to multiple transcription start sites of capped RNA as detected by CapSeq in RHBFF1+P and –P
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day 7 EBs. (D) The intragenic CGI in RHBDF1-P produced a twofold higher level of nascent sense-transcript
than in RHBDF1+P in day 7 EBs as detected by strand-specific 5’RACE. The data are normalized to Gapdh
and indicated as an average ± s.d. of two independent experiments.
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Figure S13. Hypomethylated state of promoter and alternative promoter CGIs positively correlates with
H3K4me3 enrichment, transcription initiation and negatively correlates with H3K36me3 level.
The levels of DNA methylation, enrichment of H3K36me3, Pol2, H3K4me3 and H3K27me3, and of
transcription at the promoter (A) and alternative promoter (B) CGIs sorted in descending order based on
DNA methylation levels. Each line in the pileup plot represents one CGI (+/- 2kb from the middle of the
CGI). Plots from hES cells show read distribution of H3K36me3 (in green), RNA expression (in red), Pol2
(in brown), H3K4me3 (in blue) and H3K27me3 (in purple), while DNA methylation status of individual CpGs
from BS-Seq data (in black) is plotted in black. The DNA methylation levels at promoter (C) and alternative
promoter (D) CGIs strongly correlates with H3K36me3 and anti-correlates with H3K4me3 in hES cells.
Spearman correlation coefficient and a permutation test for their significance are shown.
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Figure S14. Examples of intragenic CGIs that are transcribed, H3K36me3 enriched and DNA methylated.
Transcription through intragenic CGIs of DAZAP1 (A), SGTA and THOP1 (B) are associated with lack of
H3K4me3, enrichment in H3K36me3 level and hypermethylation.
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Figure S15. Boxplot representation of the distribution of % of GC, % of CpGs and length within the
identified classes of CGIs.
(A) The % of GC within gene body CGIs and other classes of CGIs differ significantly (p<0.001) but the
differences are between -0.33 and -0.65. This is in contrast to the 47.95 difference between CGIs and their
corresponding random sequences of the same size. (B) The % of CpGs within gene body CGIs and other
classes of CGIs differ significantly (p<0.001) but the differences are between 1.03 and 1.68. This is in
contrast to the 16.25 difference between gene body CGIs and their corresponding random sequences of
the same size. (C) The analyses showed that the sizes of the identified classes of CGIs differ significantly
(p<0.001), where the average size of the gene body CGIs is 513 +/-494 bp in contrast to the promoter CGIs
995+/- 725 bp. P value was calculated using Wilcoxon test.
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Figure S16. ACTB is expressed at higher levels than the other promoter CGIs tested in mES cells.
Real-time RT-PCR analysis of HBA2, MYOD, UBC and ACTB mES cells and EBs for clones ZFAS, MYOD-AS,
UBC-AS, and ACTB-AS respectively. Six independent clones were analysed in triplicate and the data were
normalised to Aprt and displayed as an average ± s.d.
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Figure S17. Methylation status of naturally occurring alternative promoter CGIs that are transcribed
depends on their activity relative to the upstream promoter.
Pairs of promoter and alternative promoter CGIs of the same gene are sorted in descending order based
on the differential level of Pol2 binding between these two paired CGIs. Reads distribution of H3K36me3
(in green), RNA expression (in red), Pol2 (in brown), H3K4me3 (in blue), H3K27me3 (in purple), and DNA
methylation status (in black) is plotted. Each line in the pileup plot represents one CGI (+/- 2kb from the
middle of the CGI).
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Figure S18. The % of CpG methylation, enrichment of H3K4me3 and H3K36me3 within alternative
promoter CGIs depends on the level of transcription traversing through them.
Boxplot representation of distribution of the % of CpG methylation (A), H3K36me3 (B) and H3K4me3 (C)
enrichment within the three groups of CGIs described in Fig S17. (A) % of DNA methylation within
promoter CGIs is similar regardless of expression with average methylation of 0.07% +/-0.06 (Group 1),
0.11% +/- 0.14 (Group 2) and 0.14 +/- 0.19 (Group 3). This is in contrast to alternative promoter CGIs that
exhibit average methylation level of 0.43% +/- 0.37, when the level of Pol2 is higher on the upstream
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promoter CGI (Group 3). (B) The alternative promoter CGIs with a higher Pol2 binding on the paired
promoter CGIs (Group 1) have a higher level of H3K36me3 in compare to alternative promoter CGIs in
Group 2 and 3. This is associated with a lower level of H3K4me3 (C) at these sites. p value was calculated
using Wilcoxon test.
